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Previous reports have demonstrated that the U1 cell line, a model for postintegration latency, is defective at
the level of Tat function and can be rescued by exogenously provided Tat protein. Sequence analysis of tat
cDNAs from the U1 cell line identified two distinct forms of Tat, in agreement with the fact that this cell line
contains two integrated human immunodeficiency (HIV) proviruses. One Tat cDNA lacked an ATG initiation
codon, while the other contained an H-to-L mutation at amino acid 13 (H133L). Both tat cDNAs were defective
in terms of transcriptional activation of long terminal repeat-luciferase reporter gene in transient-transfection
experiments. Introduction of the H133L mutation in a wild-type tat background caused a severe reduction in
transcriptional activation. Introduction of the same mutation in an infectious HIV molecular clone caused a
severely defective phenotype which could be rescued when the HIV proviral DNA was transfected in a Jurkat
cell line stably expressing the Tat protein (Jurkat-Tat) or in Jurkat cells treated with tumor necrosis factor
alpha. Infectious virus stocks generated in Jurkat-Tat cells were used to infect Jurkat cells and exhibited
severely impaired growth which could also be rescued by infecting Jurkat-Tat cells. These observations define
tat mutations as a mechanism for HIV postintegration latency.
It is now recognized that human immunodeficiency virus
type 1 (HIV-1) replication is continuously active at all stages of
the disease in infected individuals (8, 20). Recent experiments
using combination antiviral therapy have shown that inhibition
of new rounds of infection produces a rapid and dramatic
decrease in virus levels in plasma and lymph node (14, 26).
However, this rapid decrease is followed by a lower rate of
decrease, which has been ascribed to the persistence of chron-
ically or latently infected cells (4, 21). The lower rate of de-
crease is thought to reflect the turnover of these chronically or
latently infected cells and is a critical target in our effort to cure
individuals infected with HIV (4, 21). Recent experiments have
also documented that a significant proportion of the latent
integrated HIV-1 DNA in resting CD41 T cells is defective (4).
HIV-1 can exhibit two different forms of latency in infected
CD41 T cells, pre- and postintegration latency, depending on
the state of the provirus DNA within the infected cell. Differ-
ent culture systems have served as in vitro models for postint-
egration latency, and the study of these cells has provided
important insight into the mechanism of HIV transcriptional
regulation and pathogenesis. The U1 monocytic cell line is one
the most-studied models of postintegration latency and was
cloned from a population of chronically HIV-1-infected U937
cells (11, 12). This cell line contains two integrated HIV pro-
viruses and, under basal conditions, exhibits a pattern of viral
mRNA expression characterized by low levels of multispliced
HIV-1 transcripts encoding the regulatory proteins (22). HIV
expression can be induced at the transcriptional level in U1
cells following exposure to tumor necrosis factor alpha
(TNF-a) or phorbol esters (11, 12). This activation occurs, at
least in part, via the translocation of the transcription factor
NF-kB to the nucleus (13).
Several mechanisms have been proposed to explain this la-
tency phenotype at a molecular level. Evidence has been pre-
sented that the endogenous Tat proteins are not active in the
context of the U1 cells and that at least one of the two U1
proviruses is transcriptionally competent, indicating that the
cellular factors necessary for Tat activity are present and func-
tional in U1 cells (1–3, 7, 9).
To confirm that our U1 cell line (obtained from the AIDS
Research Reagent Program, National Institute of Allergy and
Infectious Diseases (NIAID), National Institutes of Health
(NIH), and maintained at low-passage level from frozen stock)
contained inducible latent HIV-1 proviruses, we examined the
ability of exogenous Tat protein to induce viral expression in
these cells. U1 cells treated with recombinant Tat protein (19)
released p24 antigen in their supernatant in a dose-dependent
manner (Fig. 1). Virus released after Tat treatment was non-
infectious when used in a secondary infection assay in Jurkat
cells, indicating that the virus released was most likely defec-
tive (data not shown). These observations were consistent with
the possibility that the tat open reading frame was mutated in
the two proviruses integrated in the U1 cells.
To determine the sequences of the tat cDNAs of the U1
proviruses, we performed reverse transcriptase PCR (RT-
PCR) on total mRNA extracted from U1 cells treated with 10
nM tetradecanoyl phorbol acetate for 16 h. Total RNA puri-
fied with the Trizol reagent (GIBCO/BRL) from tetradecanoyl
phorbol acetate-treated U1 cells was oligo(dT) primed to gen-
erate cDNA and was amplified by PCR using the following
HIV-specific primers flanking the tat open reading frame:
sense, 59-ACGTGGATCCTTATTCGACAGAGGAGAGCA
AGGA-39 (final nucleotide, position 5374; a new BamHI site,
introduced for cloning purpose, is indicated in boldface type),
and antisense, 59-AGATCGACCCAGATGAGTGCTAAGG
ATCCATTCA-39 (first nucleotide, position 8045). The ampli-
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fied fragment was gel purified, BamHI digested, and cloned
into the unique BamHI site of the pREP9 expression vector
downstream of the Rous sarcoma virus promoter (InVitrogen).
Twenty independent clones were sequenced by cycle sequenc-
ing (Applied Biosystems), and two different nucleotide se-
quences were identified, in agreement with the presence of two
HIV-1 proviruses integrated in U1 cells. Alignment of the
deduced Tat amino acid sequences (Fig. 2) showed them to be
most closely related to the NY5 isolate (18) and identified a
distinct single amino acid substitution for each of the proteins
compared to the HIV NY5 Tat protein. One of the tat cDNAs
(Tat1U1) is mutated at the start codon (ATG3ACG), chang-
ing the first methionine amino acid to a threonine (M13T).
The other tat cDNA (Tat2U1) harbored a mutation (CAT3
CTT) changing a histidine residue at position 13 to a leucine
residue (H133L). None of these mutations affected the se-
quence of the Rev protein.
To determine whether these two U1 Tat proteins were func-
tionally active in vivo, we first tested their abilities to transac-
tivate the HIV-1 promoter by cotransfection of a construct
containing the complete HIV-1 long terminal repeat (LTR)
(nucleotide [nt] 1 to 791) driving the luciferase reporter gene
(pLTR-Luc) and vectors expressing the different Tat proteins.
We compared the activity of a wild-type (wt) Tat (TatACH2) (9)
to the activity of each of the Tat proteins from the U1 cell
proviruses (pRep9/tat1U1 and pRep9/tat2U1). As expected,
transfection of increasing amounts of the TatACH2 expression
vector resulted in increased luciferase activity, with a maximum
68-fold transactivation (Fig. 3A). No significant transactivation
of the HIV-1 promoter was observed after cotransfection with
pRep9/tat1U1 (which contains the Tat1U1 gene with a mutated
start codon), indicating a lack of Tat expression, since Tat
contains no other initiation codon. The Tat2U1 protein
(H133L) was also defective and transactivated the HIV-1 LTR
to a significantly lower degree than did wild-type Tat (three- to
fourfold reduction) (Fig. 3A). Since there are several amino
acid differences between the primary sequences of TatACH2
and Tat2U1 (H133L) proteins, we wanted to confirm that the
H133L mutation was responsible for the decrease in trans-
activation activity of Tat2U1 (H133L). The same mutation
(H133L) was therefore introduced into the HIVNL4-3 tat open
reading frame by site-directed mutagenesis and tested in tran-
sient-transfection experiments. Introduction of this mutation
caused a severe reduction in Tat transactivating activity in
comparison to that of wt protein, as predicted, therefore con-
firming the importance of the His13 residue in Tat activity (Fig.
3B).
To examine the effect of the tat H133L mutation in the
context of virus infection, this mutation was introduced into
the HIV molecular clone, pILIC (16) by site-directed mutagen-
esis. A PvuII-PvuII fragment (nt 4501 to 7231; 11 5 mRNA
start site) containing the coding region for the first exon of the
Tat protein was subcloned into pUC19. Site-directed mutagen-
esis was performed on this vector with the Transformer kit
(Promega, Madison, Wis.) and the following oligonucleotides:
59-GCCCTGGAAGCTTCCAGGAAGTC-39 (the codon for
the leucine 13 residue is shown in boldface type) and a selec-
tion oligonucleotide changing a unique AatII site in pUC19
vector to an EcoRV site, 59-GTGCCACCTGATATCTAAGA
AACC-39. The PvuII-mutated fragment was fully resequenced,
and a PflMI-StuI fragment corresponding to nt 5459 to 6380
was purified and reintroduced into the unique PflMI-StuI sites
of pILIC. The two resulting proviral infectious clones (wt and
mutated) were electroporated into three different cell lines:
Jurkat or two Jurkat cell lines stably expressing either one-exon
Tat (Tat72) or two-exon Tat (Tat101) (19). We observed that
wt virus replicated in all three cell lines, albeit with accelerated
kinetics in Jurkat-Tat72 and Jurkat-Tat101 (data not shown).
In contrast, when the provirus HIV-TatH133L was transfected,
no virus production was detected as long as 4 weeks after
transfection in Jurkat control cells. As expected, the HIV-
TatH133L virus replicated with kinetics identical to those of wt
virus after transfection into Jurkat-Tat72 or Jurkat-Tat101
(data not shown). To determine whether this mutation was
sufficient to mimic the latent phenotype observed with U1
cells, Jurkat cells were transfected by electroporation and stim-
ulated after different times (day 3, 10, or 16 postinfection) with
TNF-a, a cytokine previously reported to induce HIV expres-
sion in U1 cells (12, 15). Detectable virus production was noted
between days 15 and 20 following transfection of wt HIV and
was significantly accelerated and amplified when cells were
FIG. 1. Induction of HIV-1 production in U1 cells by exogenous Tat protein.
One million U1 cells were incubated for 24 h with different amounts of recom-
binant Tat protein (19) in the presence of protamine sulfate (100 mg/ml) (10).
Viral production was estimated by measuring the level of p24 antigen in culture
supernatant by a commercial enzyme-linked immunosorbent assay (Dupont/
NEN).
FIG. 2. Sequences of the two tat cDNAs from the U1 proviruses. The deduced amino acid sequences (Tat1U1 and Tat2U1), presented in single-letter code, are
aligned to the closely related sequence of the HIV-1 NY5 virus Tat protein (TatNY5).
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treated with TNF-a at day 3, 10, or 16 postinfection (Fig. 4A).
In contrast, no virus production was detected following trans-
fection of the HIV-TatH133L mutant up to day 38 (Fig. 4B).
Treatment of cells transfected with this mutant clone with
TNF-a at day 3, 10, or 16 induced virus production to a level
similar to that observed following infection with wt virus. This
observation therefore demonstrates that the HIV-TatH133L
mutation is sufficient to reproduce the latent phenotype char-
acteristic of the HIV provirus integrated in U1 cells.
To confirm these findings in the context of an HIV infection,
virus stocks of both wt and mutated HIV-TatH133L were gen-
erated after transfection of their DNAs into Jurkat-Tat72 cells.
The presence of the tat mutation in these stocks was confirmed
by sequence analysis of RT-PCR-amplified tat cDNA by using
genomic viral RNA from ultracentrifuged virus as previously
described (24). Normalized amounts of each virus stock were
used to infect both Jurkat control and Jurkat-Tat101 cells. The
growth kinetics of the HIV-Tat wt virus in Jurkat control cells
showed a peak of replication at day 18 (Fig. 5A). In contrast,
infection of Jurkat cells with HIV-TatH133L produced low to
undetectable amounts of virus (Fig. 5A). A low level of virus
replication was detected at later time points (days 20 to 30).
This low-level replication is likely to result from the presence
of revertants in the virus population, since RT-PCR analysis of
Tat showed that 10% of cDNAs had lost the original mutation
that was introduced into the tat open reading frame. When the
two virus stocks were used to infect Jurkat-Tat101 cells, com-
parable kinetics of replication were observed for the two vi-
ruses (Fig. 5B), with a peak of replication at day 12 for wt virus
and at day 17 for HIV-TatH133L. These data indicated that
HIV-TatH133L was defective for replication in Jurkat control
cells and that this defective phenotype could be corrected by
providing the wt Tat protein in trans.
We have shown here that a defect in the Tat-TAR axis is
involved in the latent phenotype of the U1 cell line, a model for
postintegration latency. Determination of the sequences of the
two tat genes encoded by the HIV-1 proviruses integrated into
the U1 showed that both proviruses harbor a mutation in their
tat open reading frames. Mutation of the start codon in the
tat1U1 gene completely abolished the ability of the Tat1U1
expression vector to transactivate the HIV-1 LTR in transient-
transfection experiments because of a translation defect. The
Tat2U1 protein, which contains a single amino acid substitution
(H133L), exhibited reduced transactivating activity on the
HIV-1 LTR. When introduced into the tat gene of an infec-
tious HIV-1 clone, this substitution (H133L) markedly im-
paired virus replication. This defect was compensated for by
the constitutive expression of an active Tat protein in trans or
by TNF-a treatment, faithfully reproducing the phenotype of
the U1 provirus.
The H133L substitution in the N-terminal region of tat
modifies a domain that contains several acidic residues and
exhibits potential amphipathic helicity (23). Examination of tat
sequences from several HIV-1 isolates reveals that the histi-
dine residue at position 13 is conserved among all virus strains
(18), indicating the critical nature of this amino acid in Tat
function and presumably in HIV replication. Further study will
be required to determine how this mutation affects Tat func-
tion. However, its proximity to the Tat activation domain sug-
gests that His13 plays an important role either in the structure
of the activation domain or in its ability to interact with a
cofactor(s) critical for Tat activity.
These observations and our previously reported identifica-
tion of a TAR mutation in the ACH2 cell line (9) define the
Tat-TAR axis as a critical target in the establishment of
postintegration latency. The fact that HIV-infected latent cell
FIG. 3. Tat proteins encoded by the U1 proviruses are functionally defective. (A) Jurkat cells (5 3 106) were cotransfected by the DEAE-dextran method (25) with
1 mg of an HIV-1 LTR-luciferase reporter vector (pLTR-Luc) and 0.05, 0.15, 0.5, or 1.5 mg of a vector expressing either TatACH2 (pRep9/TatACH2 [hatched bars]),
Tat1U1 (pRep9/tat1U1 [white bars]), or Tat2U1 (pRep9/tat2U1 [black bars]). To maintain the same amount of transfected DNA and avoid squelching artifacts, the
different amounts of Tat expression vectors cotransfected were complemented to 1.5 mg of total DNA by using the empty pRep9 vector. Cells were harvested 24 h after
transfection and luciferase activity was measured according to the luciferase assay system (Promega). Values (arbitrary luminescence units) represent the means of
triplicate samples 6 standard deviations (error bars) and are normalized to protein concentrations. (B) The same protocol as that described for panel A was used for
the Tat-expressing vectors which expressed either HIVNL4-3 Tat72 protein (hatched bars) or the HIVNL4-3 Tat72 protein containing the His133L substitution (black
bars).
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lines contain defective virus genomes raises the question of
whether replication-competent HIV can establish a true state
of latent infection. True latency is indeed defined as a stable
nonproductive interaction between a fully infectious virus and
a host cell that is capable of being reversed to allow production
of infectious virus. True latency is observed with herpesviruses
and many endogenous retroviruses. Clearly, what has previ-
ously been called HIV postintegration latency does not re-
spond to these criteria and should probably be relabeled as
nonproductive defective infection. However, these observa-
tions do not exclude the possibility that a true state of latency
can be achieved by HIV in its natural host. Further study of
HIV-infected individuals should clarify this point. A high pro-
portion of the tat genes amplified from the blood of infected
individuals encode transactivation-defective Tat proteins (6).
The presence of a disabling tat mutation in a provirus results in
low levels of virus RNAs and proteins, as shown here for the
U1 cells. Low or absent virus protein expression could allow
the infected cell to escape immune surveillance and should
therefore provide a selective advantage to cells infected by
tat-defective viruses in comparison to cells infected by wt virus
(5). While the role of defective viruses in HIV pathogenesis
has not been clearly established, the selective survival of cells
infected with tat-defective viruses might be one of the mecha-
nisms used by the virus to persist in its host. Current efforts
aimed at curing HIV infection by long-term treatment with
antivirals will have to deal with this population of nonproduc-
tively infected cells as a possible source of infection reactiva-
tion after therapy has been terminated.
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FIG. 4. Replacement of histidine 13 with leucine confers a latent phenotype
to an HIV molecular clone in transfection assays. The His133L substitution was
introduced into the tat gene of an infectious molecular clone of HIV-1 (pILIC).
Jurkat cells were transfected either with wt proviral DNA (Fig. 4A) or with the
TatH133L mutated provirus (Fig. 4B) by electroporation. Cells were grown under
standard conditions (}) or treated with TNF-a (800 U/ml; Genzyme) at day 3
(n), day 10 (), or day 16 (3) after transfection. Virus replication was monitored
at different intervals (2 to 3 days) by measuring supernatant RT activity.
FIG. 5. Replacement of histidine 13 with leucine in the tat open reading
frame confers a latent phenotype to HIV in infection assays. Infectious stocks of
wt (HIV-Tatwt) and mutated (HIV-TatH133L) virus were generated following
transfection of HIV-TatH133L DNA into Jurkat-Tat72 cells. Infection of Jurkat
(Fig. 5A) or Jurkat-Tat101 cells (Fig. 5B) was carried out by incubating 106 cells
with 500,000 cpm of RT activity of HIV-Tatwt (}) or HIV-TatH133L (h) for 2 h
at 37°C in 100 ml. Virus replication was monitored at different intervals (2 to 3
days) by measuring RT activity in supernatants. A representative experiment out
of four independent experiments is shown.
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